Why Taiwan Lacks Scleral Reinforcement Surgery for Pathological Myopia - Ophthalmology

More Info

---

Scleral reinforcement surgery is a procedure designed to treat pathological myopia, a condition characterized by excessive elongation of the eyeball, leading to various ocular complications, including retinal detachment and macular degeneration. While this surgery has gained traction in some regions, such as mainland China, its absence in Taiwan raises several questions regarding the availability of treatment options for patients suffering from pathological myopia.

One of the primary reasons for the lack of scleral reinforcement surgery in Taiwan could be attributed to the differences in healthcare systems, regulatory environments, and medical practices between countries. In Taiwan, the medical community may still be assessing the long-term efficacy and safety of this procedure. The adoption of new surgical techniques often requires extensive clinical trials and regulatory approval, which can take time. Furthermore, the medical community may prioritize established treatments that have a proven track record over newer, less familiar procedures.

Additionally, the availability of specialized training and expertise in scleral reinforcement surgery may be limited in Taiwan. Surgeons need to undergo specific training to perform this procedure effectively, and if there are not enough qualified professionals, the surgery may not be offered widely. In contrast, in regions where the procedure is more common, there may be a higher concentration of trained specialists, leading to better outcomes and increased patient trust in the procedure.

Patients in Taiwan suffering from pathological myopia still have several options, even in the absence of scleral reinforcement surgery. Regular monitoring by an ophthalmologist is crucial to manage the condition and prevent complications. Patients may also benefit from other treatments, such as anti-VEGF (vascular endothelial growth factor) injections, which can help manage complications like choroidal neovascularization associated with pathological myopia.

Moreover, lifestyle modifications and preventive measures can play a significant role in managing myopia progression. Encouraging patients to engage in outdoor activities, reducing screen time, and ensuring proper lighting while reading can help mitigate the worsening of myopia. Additionally, the use of specialized contact lenses or glasses designed to slow down myopia progression may also be beneficial.

In conclusion, while the lack of scleral reinforcement surgery in Taiwan presents a challenge for patients with pathological myopia, there are still various management strategies available. It is essential for patients to work closely with their ophthalmologists to monitor their condition and explore alternative treatment options. As the medical community continues to evolve and adapt, there may be opportunities for the introduction of new surgical techniques in the future, potentially improving the landscape of treatment for pathological myopia in Taiwan.